Loading...
Loading...
REVB| Name | Value |
|---|---|
| Revenues | 27.0K |
| Cost of Revenue | 13.5K |
| Gross Profit | 13.5K |
| Operating Expense | 1,754.0K |
| Operating I/L | -1,754.0K |
| Other Income/Expense | 28.2K |
| Interest Income | 0.0K |
| Pretax | -1,726.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -1,726.0K |
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in immune system therapeutics and diagnostics. The company's product pipeline includes REVTx-99b, a Phase Ib clinical trial candidate for chronic nasal congestion and allergic rhinitis; REVTx-200, a nonclinical stage intranasal therapy; REVTx-300, a potential therapy for chronic organ diseases; and REVDx-501, a rapid test kit for respiratory viral infections. These products are designed to address unmet medical needs and have the potential to generate revenue through commercialization and sales.
